Ambrosia Shares New Data on Two Oral Obesity Drug Candidates
Boulder, Colorado, USA, November 15, 2026 Ambrosia Biosciences has announced new nonclinical findings for two investigational oral small-molecule drug...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Boulder, Colorado, USA, November 15, 2026 Ambrosia Biosciences has announced new nonclinical findings for two investigational oral small-molecule drug...
Boulder, Colorado, United States, November 10, 2026 Ambrosia Biosciences Inc., a privately held drug discovery company focused on developing...
